Faculty Opinions recommendation of Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718524891.793498409 ◽

2014 ◽

Author(s):

David Daikh

Keyword(s):

Axial Spondyloarthritis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734035996.793576229 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Axial Spondyloarthritis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-203201 ◽

2013 ◽

Vol 73 (1) ◽

pp. 101-107 ◽

Author(s):

J Sieper ◽

J Lenaerts ◽

J Wollenhaupt ◽

M Rudwaleit ◽

V I Mazurov ◽

...

Keyword(s):

Axial Spondyloarthritis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

THU0274 Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early, active axial spondyloarthritis treated with a submaximal dose of NSAIDS: Preliminary results of INFAST part I:

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2239 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 247.3-248 ◽

Author(s):

J. Sieper ◽

J. Lenaerts ◽

J. Wollenhaupt ◽

V.I. Mazurov ◽

L. Myasoutova ◽

...

Keyword(s):

Axial Spondyloarthritis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Preliminary Results

Download Full-text

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Arthritis & Rheumatology ◽

10.1002/art.40728 ◽

2018 ◽

Vol 71 (2) ◽

pp. 258-270 ◽

Author(s):

Atul Deodhar ◽

Lianne S. Gensler ◽

Joachim Sieper ◽

Michael Clark ◽

Cesar Calderon ◽

...

Keyword(s):

Axial Spondyloarthritis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.40753 ◽

2019 ◽

Vol 71 (4) ◽

pp. 599-611 ◽

Author(s):

Atul Deodhar ◽

Denis Poddubnyy ◽

Cesar Pacheco‐Tena ◽

Carlo Salvarani ◽

Eric Lespessailles ◽

...

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Mo1540 THE EFFICACY AND SAFETY OF GCWB104 (FLOS LONICERA EXTRACT) IN FUNCTIONAL DYSPEPSIA: A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Gastroenterology ◽

10.1016/s0016-5085(20)32906-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-887-S-888

Author(s):

Nayoung Kim ◽

Yonghoon Choi ◽

Dong Ho Lee

Keyword(s):

Functional Dyspepsia ◽

Controlled Study ◽

Efficacy And Safety ◽

Single Center ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56-week SCALE Obesity and Prediabetes trial

Diabetologie und Stoffwechsel ◽

10.1055/s-0035-1556574 ◽

2015 ◽

Vol 10 (04) ◽

Author(s):

P O'Neil ◽

K Fujioka ◽

R Violante Ortiz ◽

B Claudius ◽

C Jensen ◽

...

Keyword(s):

Weight Loss ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text